Format

Send to

Choose Destination
J Am Acad Dermatol. 2014 Jun;70(6):979.e1-12; quiz 9912. doi: 10.1016/j.jaad.2013.12.037.

Topical pharmacotherapy for skin cancer: part II. Clinical applications.

Author information

1
Dermatology Clinic, University of Catania, Italy. Electronic address: cldermct@nti.it.
2
Dermatology Clinic, University of Catania, Italy.
3
Department of Dermatology, Rutgers University, New Jersey Medical School, Newark, New Jersey.

Abstract

The purpose of the paper is to provide an in-depth, evidence-based analysis of the clinical use of topical treatments for skin cancer. A comprehensive review of topical drugs has been performed, including 5-fluorouracil, imiquimod, diclofenac, ingenol mebutate, retinoids, resiquimod, piroxicam, dobesilate, and betulinic acid. The evaluated studies were rated according to their level of evidence level (I-V), as indicated by recent guidelines for evidence-based medicine, The Oxford 2011 Levels of Evidence. Therapeutic response is generally related to tumor type, extent, and localization, and also to patient compliance. Careful patient selection is required in order to achieve the desired goal of complete tumor clearance.

KEYWORDS:

Bowen disease; Paget disease; actinic keratosis; basal cell carcinoma; erythroplasia of Queyrat; lentigo maligna; melanoma; skin cancer; squamous cell carcinoma; topical treatment

PMID:
24831325
DOI:
10.1016/j.jaad.2013.12.037
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center